India, Oct. 22 -- The shares of this company, which manufactures a wide range of oncology (anti-cancer) drugs in India and operates in domestic and export markets, are in the spotlight after rising 14 per cent in today's market session following strong Q2 results and management guidance. With a market capitalisation of Rs. 2,078 cr, Beta Drugs Limited shares traded at Rs. 1,876 per share, up 14% in today's session, hitting a high of Rs. 1,891.10, up from the previous close of Rs. 1,664.70. Ace investor Ashish Kacholia held a 4.43% stake under his name and 6.11% under Suryavanshi Commotrade Private Ltd in the company as of Q2FY27.

Financial Performance

Beta Drugs reported consolidated revenue from operations of Rs. 263.04 crore in H1 F...